Exchange: NASDAQ·Updated 07:30 PM EDT
PALI logo

PALI Palisade Bio Inc

$1.55
$0.09
(6.21%)
Today
Closed $1.54
$0.01
(0.65%)
After Hours
Mkt Cap$252.69M
Vol1.84M

About PALI

Palisade Bio, Inc. (Nasdaq: PALI) is a clinical-stage biopharmaceutical company advancing a next-generation oral PDE4 inhibitor prodrug designed to improve pharmacology, tolerability and convenience for patients with inflammatory and fibrotic diseases. Through its differentiated prodrug platform and precision pharmacology strategy, Palisade Bio is committed to transforming proven PDE4 biology into better, safer oral therapies for patients living with chronic inflammatory and fibrotic diseases. The Company’s lead program, PALI-2108, is a once-daily oral PDE4 inhibitor prodrug designed to be selectively bioactivated in the ileum and colon, initiating targeted PDE4 inhibition at sites of disease while enabling systemic distribution of the active drug. PALI-2108 has demonstrated positive results in a Phase 1a and two Phase 1b clinical trials, including studies in ulcerative colitis (UC) and fibrostenotic Crohn’s Disease (FSCD). Palisade Bio is now advancing towards two Phase 2 clinical studies in UC and Crohn’s disease (CD).
47

Neutral Sentiment

How do you feel about PALI?

TravisDamian
$PALI Well, I've now accumlated all I hoped to accumulate. Ready to sit on my hands for two years unless milestones miss.
2
Stock_Catcher
$PALI Palisade Bio Receives FDA Clearance of IND for PALI-2108 in Crohn’s Disease, Expanding Phase 2 Development Across IBD
2
focafoca99
$PALI appears at Stifel 2026 Virtual Immunology and Inflammation Forum to update on PALI-2108 program.
1
CorderoArkus
$PALI My bull thesis keeps getting stronger. Robert Baltera joins the board and then buys 30,000 shares in the open market around $1.98. Then look at WHO Palisade added: Baltera + Jordan Zwick. Baltera has been involved with multiple biotechs that ended in strategic acquisitions. Zwick brings deep BD, capital markets and transaction experience and advised Prometheus before its $10.8B acquisition by Merck. Why build this kind of board at a tiny clinical-stage biotech? My thesis: PALI isn't being built to commercialize PALI-2108. It's being built to DEVELOP it, DE-RISK it and SELL it. Phase 1 showed encouraging UC/CD signals. Phase 2 is the next validation step. Insider buying near $2 + transaction-heavy board additions + differentiated IBD asset = very interesting setup. I don't think $3–4 is the endgame. My bull-case M&A valuation: $8/share, with $10+ possible if Phase 2 de-risks the asset. Management may be building PALI like an acquisition target. 👀🔥
1
CorderoArkus
$PALI Each earning I am doing in scalping is to accumulate more and more $PALI. Once approved and commercialize we will be above 10USD. 3-4 years... I can wait...
CorderoArkus
$PALI Ufff, such a day. Twice we went down to 1,61 and twice we got up. Still thinking that during October we will be >2 USD. 😎
PLATINUM_TRADES
$PALI Beaten down time for a bounce we're up already but I expect this to make a run towards the $2.00 area with resistance around $1.97🚨🚨

Advertisement|Remove ads.